TOCILIZUMAB SOL INJ - ROCHE - BIOSSIMILARES
TED · 745505-2026Award noticeawardedNo deadline given
Value
Estimated—
Awarded€498,634 · 498,633.6 EUR
WinnerROCHE FARMACÊUTICA QUÍMICA, LDA.
Who already wins at this buyer
Firms with recorded awards from Unidade Local de Saúde de Coimbra, EPE in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| Brainlab Sales GmbH | 2 | €2,619,329 | 2026-10-08 |
| Cencora 3PL Portugal, S.A. | 2 | €1,435,097 | 2026-10-28 |
| Cencora 3Pl Portugal, S.A. | 2 | €823,396 | 2026-10-27 |
| Roche Farmacêutica Química, Lda. | 2 | — | 2026-10-08 |
| Takeda Farmacêuticos Portugal, Lda | 1 | €1,828,250 | 2026-07-17 |
Full buyer profile: what Unidade Local de Saúde de Coimbra, EPE buys and who wins it →
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Aquisição de Tocilizumab 162 mg/0.9 ml Sol inj Caneta 0.9 ml SC e Tocilizumab 20 mg/ml Sol inj Fr 4 ml IV
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-08-12 | Aquisição de TISLELIZUMAB 10 MGML SOL INJ FR 10 ML IV 2026 - NOVO | Unidade Local de Saúde de Gaia/Espinho, EPE PT | 93% |
| 2026-09-14 | Com base no cpa 2025_1303 - Glofitamab - justificação clinica | Unidade Local de Saúde de Coimbra, EPE PT | 93% |
| 2026-09-17 | C/ BASE NO CPA 2024_961 - INCLISIRAN 189 MG/ML SOL INJ SER 1.5 ML SC | Unidade Local de Saúde de Coimbra, EPE PT | 93% |
| 2026-10-20 | 2025/1746 - EMICIZUMAB [150 MG/ML 1 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-10-28 | C/ BASE NO CPA 2026_6 | Unidade Local de Saúde de Coimbra, EPE PT | 93% |
| 2026-06-09 | 2025/1746 -EMICIZUMAB [150 MG/ML 0,4 ML SOL INJ FRS] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 92% |